CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020. The implementation date has been moved up to July 7th. Contact your Customer Service Manager if you have any questions!
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...